 |
|
| PRODUCT BRANDS | |
 | Azzalure ® |
 | |
| Bocouture® |
| |
| Botox ® |
| |
| Dysport ® |
| |
| Neurobloc ® |
| |
| Vistabel ® |
| |
| Xeomin® |
| |
| CLINICS | |
|
Recruitment |
|
|
|
Equipment Sales |
|
|
|
Register |
|
|
|
Clinic Login |
|
|
| SUPPLIERS | |
|
Register |
|
|
|
Supplier Login |
|
|
| NEWSLETTER | |
|
Consumer |
|
|
|
Press |
|
|
| GENERAL | |
|
Contact Us |
|
|
|
Media Services |
|
|
About Us |
|
|
|
Our Philosophy |
|
|
|
Our Advisers |
|
|
|
Privacy Policy |
|
|
|
Site Guide |
|
|
| © Copyright 2003-2010 Consultingroom.com™ Ltd |
 |
 |
 |
| NAVIGATOR: Home: Treatment FAQs: Non Surgical: Botulinum Toxin: Dysport ® | 09 September 2010 | ||
Dysport ® Information and BackgroundDysport® is a registered trademark of Ipsen Ltd.
Product Summary
Dysport®, botulinum toxin type A, has been available in the U.K. since the early 1990's and has licences in 67 countries worldwide including the United Kingdom and many European markets. It is manufactured by the French company Ipsen. The product is licensed for cosmetic use in a number of markets e.g. glabellar (frown) lines in Germany. It also gained approval for cosmetic use in the UK in early 2009 and is marketed for this indication, with a dosing specific to treat glabellar lines, under the brand name Azzalure® by Galderma.
Generic name
Clostridium botulinum type - A neurotoxin complex How is it manufactured? Dysport® is made from purified type - A neurotoxin produced by the bacteria Clostridium Botulinum. How does it work? It temporarily prevents the release of acetycholine from sympathetic nerve terminals. Licenced status Prescription only medicine Who can administer the drug? It should be used by trained members of the medical profession only. Dysport® doctors, nurses and dentists can be found using our Find a Dysport® Clinic search to view clinics that offer the treatment within the UK and Ireland.
Licenced UK indications Dysport® is licenced in the UK for blepharospasm, hemifacial spasm, cervical dystonia, dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, two years of age or older; and focal spasticity, including the treatment of arm symptoms associated with focal spasticity, in conjunction with physiotherapy. It can be used off-label for cosmetic use.
It also gained licensing for cosmetic use in the UK in early 2009 and is marketed for this indication, with a dosing (vial size) specific to treat glabellar lines, under the brand name Azzalure®.
Who should not be treated? Individuals with a known hypersensitivity to any component of the formulation. Patients who have generalised disorders of muscle activity (e.g. myasthenia gravis). Patients where aminoglycoside antibiotics or spectinomycin are already being used or are likely to be used.
Patients who have bleeding disorders of any type. Pregnant or lactating women.
Reported side effects associated with cosmetic use include Bruising or bleeding at the site of injection, headache, and rarely eyelid ptosis or diplopia, and brow droop. Costs
Most clinics and practitioners charge by area of the face treated. These areas are usually defined as crow’s feet, forehead lines, and glabellar lines (frown lines between the eyes).
|
|
